Finnish pharmaceuticals company Orion Corporation and Indian biotech company Aurigene have entered into an option and research & collaboration agreement.
The agreement regards rights to Aurigene’s Pan BET and Selective BET Bromodomain inhibitors program. Under the terms of the option agreement, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the Candidate selection stage for the BET inhibitors. Orion will collaborate with Aurigene and fund the selective BET program at Aurigene, with Aurigene being eligible for development phase milestones and royalties.
“Aurigene and Orion have worked together in a number of programs over the past several years, with some of our early collaborations expected to reach the clinical development phase soon. Aurigene’s ability to work closely with our Scientific teams, in this exciting area of cancer therapy, will add value to Orion’s pipeline,” said Dr. Pekka Kallio Head of Oncology and Critical Care Research, of Orion.